Advicenne S.A. (ALDVI.PA)
EUR 1.75
(-0.79%)
EUR 1.75
(-0.79%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.42 Million EUR | 113.52% |
| 2022 | 1.28 Million EUR | -25.41% |
| 2021 | 1.71 Million EUR | 45.92% |
| 2020 | 1.17 Million EUR | 110.84% |
| 2019 | -10.85 Million EUR | -49.29% |
| 2018 | -7.26 Million EUR | -99.25% |
| 2017 | -3.64 Million EUR | -2258.35% |
| 2016 | 169 Thousand EUR | 160.0% |
| 2015 | 65 Thousand EUR | 115.01% |
| 2014 | -433.18 Thousand EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 351 Thousand EUR | 0.0% |
| 2024 Q1 | 351 Thousand EUR | 71.64% |
| 2023 Q1 | 566 Thousand EUR | 262.82% |
| 2023 Q2 | 900 Thousand EUR | 59.01% |
| 2023 Q3 | 204.5 Thousand EUR | -77.28% |
| 2023 FY | 2.73 Million EUR | 113.52% |
| 2023 Q4 | 204.5 Thousand EUR | 0.0% |
| 2022 Q3 | 267.99 Thousand EUR | -58.77% |
| 2022 Q1 | 645 Thousand EUR | -3.59% |
| 2022 FY | 1.28 Million EUR | -25.41% |
| 2022 Q4 | 156 Thousand EUR | -41.79% |
| 2022 Q2 | 650 Thousand EUR | 0.78% |
| 2021 FY | 1.71 Million EUR | 45.92% |
| 2021 Q4 | 669 Thousand EUR | -14.29% |
| 2021 Q3 | 780.5 Thousand EUR | 31.4% |
| 2021 Q2 | 594 Thousand EUR | -0.67% |
| 2021 Q1 | 598 Thousand EUR | 140.16% |
| 2020 Q4 | 249 Thousand EUR | 107.57% |
| 2020 Q1 | 596.5 Thousand EUR | 46.92% |
| 2020 Q3 | -3.28 Million EUR | -753.68% |
| 2020 Q2 | 503 Thousand EUR | -15.67% |
| 2020 FY | 1.17 Million EUR | 110.84% |
| 2019 Q3 | 552 Thousand EUR | 67.78% |
| 2019 Q1 | 390 Thousand EUR | 109.94% |
| 2019 FY | -10.85 Million EUR | -49.29% |
| 2019 Q4 | 406 Thousand EUR | -26.45% |
| 2019 Q2 | 329 Thousand EUR | -15.64% |
| 2018 Q4 | -3.92 Million EUR | 0.0% |
| 2018 Q3 | -3.92 Million EUR | -1237.26% |
| 2018 Q1 | 345 Thousand EUR | -39.37% |
| 2018 Q2 | 345 Thousand EUR | 0.0% |
| 2018 FY | -7.26 Million EUR | -99.25% |
| 2017 Q4 | 569 Thousand EUR | 0.0% |
| 2017 Q2 | 530.5 Thousand EUR | 0.0% |
| 2017 Q1 | 530.5 Thousand EUR | 14.21% |
| 2017 FY | -3.64 Million EUR | -2258.35% |
| 2017 Q3 | 569 Thousand EUR | 7.26% |
| 2016 FY | 169 Thousand EUR | 160.0% |
| 2016 Q1 | 426.5 Thousand EUR | 0.0% |
| 2016 Q2 | 426.5 Thousand EUR | 0.0% |
| 2016 Q3 | 464.5 Thousand EUR | 8.91% |
| 2016 Q4 | 464.5 Thousand EUR | 0.0% |
| 2015 FY | 65 Thousand EUR | 115.01% |
| 2014 FY | -433.18 Thousand EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ABIONYX Pharma SA | 618 Thousand EUR | -130.744% |
| ABIVAX Société Anonyme | 3.91 Million EUR | 63.567% |
| Adocia SA | 1.38 Million EUR | -2.96% |
| Aelis Farma SA | 12.35 Million EUR | 88.461% |
| Biophytis S.A. | -803 Thousand EUR | 277.584% |
| genOway Société anonyme | 20.1 Million EUR | 92.906% |
| IntegraGen SA | 5.01 Million EUR | 71.584% |
| Medesis Pharma S.A. | -2.66 Million EUR | 153.513% |
| Neovacs S.A. | 29.31 Thousand EUR | -4764.57% |
| NFL Biosciences SA | -56.06 Thousand EUR | 2643.522% |
| Plant Advanced Technologies SA | 2.15 Million EUR | 33.764% |
| Quantum Genomics Société Anonyme | -1.41 Million EUR | 200.473% |
| Sensorion SA | 3.78 Million EUR | 62.353% |
| Theranexus Société Anonyme | -4.63 Million EUR | 130.741% |
| TME Pharma N.V. | -127 Thousand EUR | 1222.835% |
| Valbiotis SA | 2.66 Million EUR | 46.552% |
| TheraVet SA | -530.79 Thousand EUR | 368.653% |
| Valerio Therapeutics Société anonyme | 1.26 Million EUR | -12.549% |
| DBV Technologies S.A. | 4.15 Million EUR | 65.718% |
| Genfit S.A. | 28.22 Million EUR | 94.948% |
| GeNeuro SA | -293.8 Thousand EUR | 585.364% |
| Innate Pharma S.A. | -4.12 Million EUR | 134.603% |
| Inventiva S.A. | 17.5 Million EUR | 91.851% |
| MaaT Pharma SA | 1.65 Million EUR | 13.837% |
| MedinCell S.A. | 9.28 Million EUR | 84.647% |
| Nanobiotix S.A. | 36.2 Million EUR | 96.062% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | 35.968% |
| Poxel S.A. | 1000.00 EUR | -142500.0% |
| GenSight Biologics S.A. | 3 Million EUR | 52.467% |
| Transgene SA | -28.4 Million EUR | 105.02% |
| Valneva SE | 52.83 Million EUR | 97.301% |